Background information on HIV, hepatitis C and STIs in Canada, including basic information, statistics (epidemiology), provincial and national strategies to address HIV, hepatitis C and STIs, and social determinants of health.
Information on HIV and hepatitis C transmission and prevention, including STIs and safer sex, harm reduction, pregnancy and infant feeding, and microbicides and vaccines.
Information on diagnostic tests for HIV, hepatitis C and STIs; the delivery of testing and counselling; and resources for people who are newly diagnosed.
Information on treatment, care and support for HIV, hepatitis C and STIs, including medications, healthy living, pregnancy and infant feeding, hepatitis C re-infection, and long-term health issues.
CATIE’s online educational courses, webinars, online and print publications, and other websites.
CATIE strengthens Canada’s response to HIV and hepatitis C by bridging research and practice. We connect healthcare and community-based service providers with the latest science, and promote good practices for prevention and treatment programs.
This chart summarizes potential drug interactions between tenofovir/emtricitabine (TDF/FTC) for PrEP and key long-term use medications, such as pain medication.
